Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Awiqli coverage & Prior Auth update | O…
    Ask Trek AI about this page
    CurrentQualChoicePolicy HIM.PA.180

    Insulin icodec-abae (Awiqli) coverage criteria

    Customize your policy alerts

    Sign up for QualChoice Policy HIM.PA.180 alerts

    Get alerted when Policy HIM.PA.180 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, prior authorization, and coverage criteria for Awiqli (insulin icodec-abae) for adults with type 2 diabetes mellitus under QualChoice HIM/ICHRA lines of business; applies to providers requesting coverage and prior authorization.

    Policy Summary
    PayerQualChoice
    PolicyInsulin icodec-abae (Awiqli) coverage criteria
    Policy CodePolicy HIM.PA.180
    Change TypeMinor editorial — no material coverage changes
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation (office notes, labs, or other clinical information) showing member meets initial or continuation criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18Minimum age
    12 monthsApproval duration
    RequiredStep therapy
    Once-weeklyDosing frequency

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2
    HCPCS entries

    Coverage Criteria for Awiqli (insulin icodec-abae)

    Initial Therapy

    Covered when ALL of the following are met

    Type 2 Diabetes Mellitus initial: 1. Diagnosis of type 2 diabetes mellitus; 2. Age ≥ 18 years; 3. Failure of both of the following unless contraindicated or clinically significant adverse effects are experienced: a) insulin glargine-ygfn (unbranded Semglee); b) branded Tresiba (insulin degludec).

    For Illinois HIM requests, the step therapy requirements do not apply as of 1/1/2026 per IL HB 5395.

    Continuation Therapy

    Covered when ALL of the following are met

    Type 2 Diabetes Mellitus continued: 1. Member meets one of the following: a) currently receiving medication via Centene benefit or previously met initial approval criteria; OR b) member is currently receiving medication and is enrolled in a state/product with continuity of care regulations; 2. Member is responding positively to therapy; 3. Failure of both of the following unless contraindicated or clinically significant adverse effects are experienced: a) insulin glargine-ygfn (unbranded Semglee); b) branded Tresiba (insulin degludec).

    For Illinois HIM requests, the step therapy requirements do not apply as of 1/1/2026 per IL HB 5395.

    Not Authorized Indications

    Not covered when the following apply

    Non‑FDA indications: Non‑FDA approved indications that are not addressed in this policy are not authorized unless there is sufficient documentation of efficacy and safety according to the off‑label use policy HIM.PA.154 or applicable evidence of coverage documents.

    Non‑FDA approved indications are not covered by this policy unless there is sufficient documentation of efficacy and safety in accordance with the Health Plan’s off‑label use policy HIM.PA.154 (health insurance marketplace/ICHRA) or the member’s evidence of coverage documents.

    Coverage and benefit administration for requests reviewed under this policy are governed by the member’s coverage documents and applicable law. Benefits are subject to all terms, conditions, exclusions, and limitations in the member’s evidence of coverage, certificate of coverage, policy or contract, as well as applicable state and federal requirements and Health Plan administrative policies and procedures.

    Requests for Awiqli to treat non‑FDA approved indications without adequate supporting documentation of efficacy and safety will be considered not medically necessary unless the submission meets the documentation standards set forth in off‑label use policy HIM.PA.154 or the member’s evidence of coverage explicitly allows such use.

    Coding and Dosing Guidance

    HCPCS Codes referencedHCPCS
    J3590Unclassified biologics
    C9399Unclassified drugs or biologicals
    HCPCS Codes referencedHCPCS
    J3590Unclassified biologics
    C9399Unclassified drugs or biologicals
    Maximum single-dose handling
    Maximum single-dose handlingWhen required dose > 700 units, split into two injections.
    RationalePrefilled pen sizes contain 700 units/mL; doses exceeding a single-pen capacity should be divided to avoid overfilling a single injection.
    Reference dosing frequencyAwiqli is administered subcutaneously once-weekly; plan dosing to adhere to weekly schedule when splitting doses.

    Provider Actions and Prior Authorization Requirements

    Prior Authorization

    Prior authorization required

    Prior authorization is required. Submit a prior authorization request with documentation demonstrating the member meets the policy’s initial or continued therapy criteria (diagnosis of type 2 diabetes mellitus, age ≥ 18 years, and required prior therapy failures/contraindications).

    • Include evidence of prior therapy failures or contraindications to required agents when applicable.
    • Approval duration when authorized: 12 months.
    Note

    Authorization and coding guidance

    This clinical policy is used to guide medical necessity determinations, but providers must follow the Health Plan’s authorization processes and contract terms for coverage decisions and claims submission.

    • Codes shown in the policy are informational only; follow current professional coding guidance prior to claim submission.
    • The Health Plan may change or withdraw the policy; effective dates and applicable legal/regulatory requirements govern.

    Initial Therapy Approval Criteria

    Initial Therapy

    Initial therapy covered when criteria are met

    Initial therapy nodes: 1. Diagnosis of type 2 diabetes mellitus; 2. Age ≥ 18 years; 3. Failure of both insulin glargine-ygfn (Semglee) AND branded Tresiba (insulin degludec) unless contraindicated or clinically significant adverse effects; 4. Provider must submit supporting clinical documentation (e.g., office chart notes, lab results) showing criteria are met.

    Approval duration: 12 months. For Illinois HIM requests, the step therapy requirements do not apply as of 1/1/2026 per IL HB 5395.

    Continuation / Renewal Criteria

    Continuation Therapy

    Continued therapy covered when criteria are met

    Continued therapy nodes: 1. Member currently receiving medication via Centene benefit or previously met initial approval criteria OR member has continuity of care as defined by state/product addenda; 2. Member is responding positively to therapy; 3. Failure of both insulin glargine-ygfn (Semglee) AND branded Tresiba (insulin degludec) unless contraindicated or clinically significant adverse effects.

    Approval duration: 12 months. For Illinois HIM requests, the step therapy requirements do not apply as of 1/1/2026 per IL HB 5395.

    Step Therapy Requirements

    StepRequired prior therapy (failure or contraindication)Notes / Exceptions
    1Insulin glargine-ygfn (unbranded Semglee) — failure or contraindicationMust document failure of both agents or contraindications prior to approval; Illinois HIM requests are exempt from step therapy per IL HB 5395 (effective 1/1/2026).
    1Branded Tresiba (insulin degludec) — failure or contraindicationMust document failure of both agents or contraindications prior to approval; Illinois HIM requests are exempt from step therapy per IL HB 5395 (effective 1/1/2026).

    Quantity Limits and Dispensing Guidance

    Awiqli — dose splitting and product guidance
    When to split dosesWhen required dose > 700 units, split into two injections.
    Product concentrationAwiqli available as 700 units/mL prefilled FlexTouch pens.
    Pen sizesPrefilled pens: 1 mL (700 units), 1.5 mL (1,050 units), and 3 mL (2,100 units).
    Administration notePlan injections so individual injection volumes do not exceed single‑use pen capacity; follow weekly dosing schedule when dividing doses.

    Background

    Awiqli (insulin icodec‑abae) is a long‑acting human insulin analog indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is administered subcutaneously once weekly and is supplied as a high‑concentration formulation in prefilled pens (700 units/mL). Approval under this policy is for adults meeting the policy’s coverage criteria and prior authorization requirements.

    Definitions

    Awiqli (insulin icodec-abae) — definition & indication
    Drug name (generic/brand)Insulin icodec-abae (Awiqli)
    ClassLong-acting human insulin analog (insulin)
    IndicationAdjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
    Route and frequencySubcutaneous administration, once-weekly.
    Health Plan — definition
    Health Plan definitionA health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or affiliates.
    Scope
    Policy Summary
    PayerQualChoice
    PolicyInsulin icodec-abae (Awiqli) coverage criteria
    Policy CodePolicy HIM.PA.180
    Change TypeMinor editorial — no material coverage changes
    Effective DateJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation (office notes, labs, or other clinical information) showing member meets initial or continuation criteria.
    SourceLink
    On This Page
    Coverage Criteria for Awiqli (insulin icodec-abae)Coding and Dosing GuidanceProvider Actions and Prior Authorization RequirementsInitial Therapy Approval CriteriaContinuation / Renewal CriteriaStep Therapy RequirementsQuantity Limits and Dispensing GuidanceBackgroundDefinitions
    Step Therapy

    Step therapy: document failure of Semglee and Tresiba

    Step therapy must be documented: before approval for initial or continued therapy, the member must have failure of both insulin glargine-ygfn (unbranded Semglee) and branded Tresiba (insulin degludec), unless contraindicated or clinically significant adverse effects are documented. Illinois HIM requests are exempt from step therapy as of 1/1/2026 per IL HB 5395.

    • Document trial durations, outcomes, and reasons for discontinuation or intolerability for each agent.
    • If both agents are contraindicated, provide clinical justification in the request.
    Note

    Include continuity and state-specific information when applicable

    Provide any additional clinically relevant notes or justifications in the authorization request to support medical necessity decisions (e.g., continuity of care, enrollment in state/product continuity programs).

    • If member is currently receiving medication via Centene benefit or has prior approval history, indicate this in the request.
    • Refer to state-specific continuity of care addendums when applicable.
    Documentation Required

    Required clinical documentation to support PA

    Submit supporting clinical documentation with the prior authorization request—examples include office chart notes, lab results, and other clinical information demonstrating the member meets all approval criteria.

    • Documentation should show diagnosis, age, response to therapy (for continuation), and trials or contraindications to required prior agents.
    • Include blood glucose/HbA1c results or other objective measures when available.
    Note

    Coverage subject to member contract terms

    Coverage determinations and administration of benefits are governed by the member’s coverage documents and applicable Health Plan-level policies; verify contract terms and evidence of coverage when submitting requests.

    • Coverage is subject to terms, conditions, exclusions, and limitations in evidence of coverage, certificate of coverage, policy, or contract.
    • State and federal requirements and plan-level administrative policies may supersede or affect coverage.
    Denial Risk

    Denial risk for incomplete documentation or non‑FDA indications

    Requests missing required documentation that the member meets all approval criteria, or requests for non‑FDA approved indications without sufficient evidence per the off‑label use policy, may be denied.

    • Non‑FDA indications require adequate documentation of efficacy and safety per HIM.PA.154 or evidence of coverage to be considered.
    • Ensure all approval criteria are clearly documented to avoid administrative denials.
    Billing Rule

    Coding may affect claims — verify codes before billing

    The HCPCS codes listed in this policy are informational; inclusion or exclusion of codes does not guarantee coverage. Verify current coding guidance before submitting claims, as incorrect coding may affect reimbursement.

    • Codes referenced: J3590 (Unclassified biologics) and C9399 (Unclassified drugs or biologicals).
    • Providers should reference the most up-to-date sources of professional coding guidance prior to claim submission.
    Applies to Health Plans using this clinical policy to guide medical necessity determinations and benefit administration.
    LimitationsThis policy is a guide and does not constitute a contract or guarantee of payment; providers must follow plan-specific authorization processes and contract terms.